84449-90-1

84449-90-1 structure

Name: Raloxifene
Chemical Name: raloxifene
CAS Number: 84449-90-1
Molecular Formula: C₂₈H₂₇NO₄S
Molecular Weight: 473.583
Catalog: API Antineoplastic agents Hormone antineoplastic agents
Create Date: 2018-04-16 08:00:00
Modify Date: 2025-08-21 13:51:07
Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].

Name	raloxifene
Synonyms	[2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Raloxifeno [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidino-ethoxy)benzoyl]benzo[b]thiophene [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone [6-Hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]{4-[2-(1-piperidinyl)ethoxy]phenyl}methanone [6-Hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]{4-[2-(piperidin-1-yl)ethoxy]phenyl}methanone UNII-YX9162EO3I Raloxifenum [Latin] Raloxifene [INN:BAN] [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone Raloxifeno [Spanish] Keoxifene [3H]-Raloxifene MFCD00866415 Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)- Raloxifene [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone Raloxifenum [14C]-Raloxifene Raloxifene HCl

Description	Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
Related Catalog	Signaling Pathways >> Others >> Estrogen Receptor/ERR Research Areas >> Cancer
Target	Estrogen receptor
In Vivo	Raloxifene (4 mg/kg; intragastrically; daily for 13 weeks) significantly prevents bone loss in ovariectomized (OVX) rats[1]. Animal Model: Female, 12-week-old, Wistar rats (OVX rats)[1] Dosage: 4 mg/kg Administration: Intragastrically; daily for 13 weeks Result: Significantly increased the levels of E2 in OVX rats and significantly decreased the levels of BGP.
References	[1]. Khovidhunkit W, et al. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130(5):431-439. [2]. Xu H, et al. Effect of caffeine on ovariectomy-induced osteoporosis in rats. Biomed Pharmacother. 2019;112:108650.

WGK Germany	3